Research programme: cancer immunotherapeutics - Pfizer

Drug Profile

Research programme: cancer immunotherapeutics - Pfizer

Alternative Names: Anti-CD134 monoclonal antibody - Pfizer; Anti-macrophage colony stimulating factor antibody- Pfizer; anti-MCSF-antibody- Pfizer; Anti-OX40 monoclonal antibody - Pfizer; Anti-PD1 monoclonal antibody - Pfizer; CCR2-inhibitor- Pfizer; Prostate cancer vaccine - Pfizer

Latest Information Update: 03 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Bispecific antibodies; Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; OX40 receptor antagonists; Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Prostate cancer

Most Recent Events

  • 22 Jun 2018 Alexo Therapeutics is now called ALX Oncology
  • 06 Sep 2017 Pfizer plans a phase I trial of PF 06863135 for Multiple myeloma (Refractory metastatic disease, Late-stage disease, Second-line therapy or greater) (NCT03269136)
  • 19 Nov 2014 Pfizer and Merck KGaA enter into a collaboration to advance Pfizer's anti-PD1 antibody into phase I trials
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top